Globe Life’s Q4 performance was met with a positive market response, despite revenue and non-GAAP profit coming in slightly below Wall Street expectations. Management attributed the quarter’s growth to strong sales activity in the Medicare Supplement business, higher agent productivity, and continued margin discipline across both life and health segments. In particular, CEO Matt Darden highlighted improvements in technology for lead generation and conversion, as well as favorable mortality trends that drove underwriting margin gains. While there were some increases in agent turnover and seasonal claims volatility, management viewed these as manageable fluctuations within their long-term growth strategy.

Is now the time to buy GL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Globe Life’s Q4 Earnings Call

• Jamminder Bhullar (JPMorgan) asked about higher lapse rates in direct-to-consumer sales. CFO Thomas Kalmbach explained that online channels tend to have higher lapses, but overall sales growth and underwriting margins remain positive.

• Wilma Jackson Burdis (Raymond James) questioned whether technology-driven efficiencies in lead generation and agent productivity still have room to improve. CEO Matt Darden stated that additional technology enhancements are planned for 2026 and 2027, which should further support sales growth.

• Francis Matten (BMO) inquired about the decline in American Income’s agent count and the specifics of retention initiatives. Darden responded that agent turnover was typical for year-end and that new incentives targeting middle management are being introduced to boost retention.

• Andrew Kligerman (TD Cowen) sought more detail on the relationship between agent productivity and sales growth. Darden clarified that improved lead quality and higher average premiums per sale drove productivity gains, and that agent count growth is expected to be steady but slower than sales growth.

• Wesley Carmichael (Wells Fargo) asked about the Bermuda reinsurance affiliate’s impact on future cash flow. Kalmbach said that while no significant benefit is expected in 2026, incremental contributions could materialize in 2027 and beyond, pending regulatory approval.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will be watching (1) the pace of Medicare Supplement sales growth and the impact of premium rate increases, (2) the effectiveness of new agent retention initiatives and productivity enhancements, and (3) the progression of Bermuda reinsurance transactions and their contribution to excess cash flow. Continued monitoring of claim trends and regulatory developments in the Medicare market will also be critical markers for Globe Life’s execution.

Globe Life currently trades at $141.94, down from $144.82 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.